WINTON GROUP Ltd Invests $899,000 in Oric Pharmaceuticals, Inc. $ORIC

WINTON GROUP Ltd acquired a new position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the second quarter, HoldingsChannel.com reports. The fund acquired 83,000 shares of the company’s stock, valued at approximately $899,000.

Other large investors have also added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in Oric Pharmaceuticals in the 2nd quarter valued at $694,000. Integrated Wealth Concepts LLC bought a new stake in Oric Pharmaceuticals during the 2nd quarter worth about $38,000. Squarepoint Ops LLC acquired a new position in shares of Oric Pharmaceuticals during the 2nd quarter worth about $3,729,000. California State Teachers Retirement System boosted its stake in shares of Oric Pharmaceuticals by 1,513.5% during the 2nd quarter. California State Teachers Retirement System now owns 780,410 shares of the company’s stock worth $8,452,000 after buying an additional 732,041 shares during the last quarter. Finally, AXQ Capital LP bought a new position in shares of Oric Pharmaceuticals in the 2nd quarter valued at about $396,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $12.65 on Tuesday. The firm has a 50-day moving average of $12.40 and a 200-day moving average of $10.87. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.93. The company has a market cap of $1.31 billion, a PE ratio of -9.37 and a beta of 1.00.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). Analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Insiders Place Their Bets

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 77,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the transaction, the chief financial officer owned 69,828 shares of the company’s stock, valued at $955,945.32. The trade was a 52.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ORIC has been the topic of a number of recent research reports. Stifel Nicolaus initiated coverage on Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. HC Wainwright boosted their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.60.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.

Oric’s research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).